Advertisement

ADVERTISEMENT

lung cancer

Research in Review
Drug Trials Show Promising Results for Lung Cancer Treatment
10/01/2015
JCP Editors
Atezolizumab, a monoclonal antibody developed by Roche that is currently in clinical trails, could be set to change the landscape of lung cancer treatment for physicians and patients. A pair of German investigators...
Atezolizumab, a monoclonal antibody developed by Roche that is currently in clinical trails, could be set to change the landscape of lung cancer treatment for physicians and patients. A pair of German investigators...
...
10/01/2015
Journal of Clinical Pathways
Clinical Insights
Advances in the Treatment of Early Stage Non-Small Cell Lung Cancer Using Stereotactic Radiation Therapy
09/30/2015

Brian Edward Lally, MD

From the Department of Radiation Oncology, Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina.

Brian Edward Lally, MDFrom the Depart...
Abstract: Surgery is still the most commonly used treatment for early-stage non-small cell lung cancer (NSCLC). However, many patients with NSCLC have significant comorbidities and are not surgical candidates. Radiation therapy has...
Abstract: Surgery is still the most commonly used treatment for early-stage non-small cell lung cancer (NSCLC). However, many patients with NSCLC have significant comorbidities and are not surgical candidates. Radiation therapy has...
Abstract: Surgery is still the...
09/30/2015
IO Learning
News
Cellular Biomedicine Group Announces Positive Results from CAR-T EGFR Immunotherapy Phase I Clinical Trial for Non-Small Cell Lung Cancer
09/28/2015
SHANGHAI, China and PALO ALTO, Calif., September 28, 2015 /GlobeNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell...
SHANGHAI, China and PALO ALTO, Calif., September 28, 2015 /GlobeNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell...
SHANGHAI, China and PALO ALTO,...
09/28/2015
IO Learning
Research in Review
What Separates Low-Mortality from High-Mortality Hospitals After Lung Cancer Resection?
09/18/2015
JCP Editors
According to a recent report in the online JAMA Surgery, differences in mortality rates after lung cancer resection at hospitals across the country boil down to one key factor: a difference in failure-to-rescue...
According to a recent report in the online JAMA Surgery, differences in mortality rates after lung cancer resection at hospitals across the country boil down to one key factor: a difference in failure-to-rescue...
...
09/18/2015
Journal of Clinical Pathways
Research in Review
‘Basket Study’ Shows Treatment Response in Certain Patients with Advanced Lung Cancer
09/17/2015
Jolynn Tumolo
Citations: Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. New Engl J Med. 2015;373:726–736. More than one-third of patients with advanced lung...
Citations: Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. New Engl J Med. 2015;373:726–736. More than one-third of patients with advanced lung...
...
09/17/2015
Journal of Clinical Pathways
Research in Review
Timeliness, Thoroughness Lacking in Lung Cancer Care
09/16/2015
JCP Editors
Averaging more than 2.5 months, the span of time between initial lesion detection and lung resection in patients with lung cancer is often too long, according to researchers who reviewed hospital records at one...
Averaging more than 2.5 months, the span of time between initial lesion detection and lung resection in patients with lung cancer is often too long, according to researchers who reviewed hospital records at one...
...
09/16/2015
Journal of Clinical Pathways
News
Alliance HealthCare Services and Dignity Health Bay Area Bring CyberKnife Cancer Treatment to Saint Francis Memorial Hospital
06/16/2015
San Francisco CyberKnife treatment center to offer radiation therapy for Northern California patientsJune 16, 2015 08:00 AM Eastern Daylight Time: NEWPORT BEACH, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Alliance Oncology, a division of...
San Francisco CyberKnife treatment center to offer radiation therapy for Northern California patientsJune 16, 2015 08:00 AM Eastern Daylight Time: NEWPORT BEACH, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Alliance Oncology, a division of...
San Francisco CyberKnife...
06/16/2015
IO Learning
News
Stereotactic Ablative Radiotherapy Achieves Better Overall Survival Than Surgery for Early Lung Cancer
05/14/2015
First randomized clinical trial comparing the two therapies suggests that the non-invasive SABR treatment should be considered an alternative to surgery, especially for elderly patients and those with comorbiditiesMay 13, 2015 - Newswise —...
First randomized clinical trial comparing the two therapies suggests that the non-invasive SABR treatment should be considered an alternative to surgery, especially for elderly patients and those with comorbiditiesMay 13, 2015 - Newswise —...
First randomized clinical trial...
05/14/2015
IO Learning
News
Medical Nanoparticles: Local Treatment of Lung Cancer
03/10/2015
 Neuherberg, Germany, 2 March 2015. Nanoparticles can function as carriers for medicines to combat lung cancer: Working in a joint project at the NIM (Nanosystems Initiative Munich) Excellence Cluster, scientists from the Helmholtz...
 Neuherberg, Germany, 2 March 2015. Nanoparticles can function as carriers for medicines to combat lung cancer: Working in a joint project at the NIM (Nanosystems Initiative Munich) Excellence Cluster, scientists from the Helmholtz...
 Neuherberg, Germany, 2...
03/10/2015
IO Learning
Clinical Insights
Ablation for Lung Tumors: An Interview With Constantinos T. Sofocleous, MD, PhD
03/05/2015

Interview by Jennifer Ford

Interview by Jennifer Ford
Editor's note: View video of this interview here.At the 2015 Symposium on Clinical Interventional Oncology, part of the International Symposium on Endovascular Therapy, Constantinos T. Sofocleous, MD, PhD, of the Memorial Sloan Kettering...
Editor's note: View video of this interview here.At the 2015 Symposium on Clinical Interventional Oncology, part of the International Symposium on Endovascular Therapy, Constantinos T. Sofocleous, MD, PhD, of the Memorial Sloan Kettering...
Editor's note: View video of...
03/05/2015
IO Learning

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use